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Abstract
Background: Identifying biomarkers for autism can improve outcomes for those affected by autism. Engaging the
diverse stakeholders in the research process using community-based participatory research (CBPR) can accelerate
biomarker discovery into clinical applications. However, there are limited examples of stakeholder involvement in
autism research, possibly due to conceptual and practical concerns. We evaluate the applicability of CBPR principles
to biomarker discovery in autism and critically review empirical studies adopting these principles.
Methods: Using a scoping review methodology, we identified and evaluated seven studies using CBPR principles
in biomarker discovery.
Results and conclusions: The limited number of studies in biomarker discovery adopting CBPR principles coupled
with their methodological limitations suggests that such applications are feasible but challenging. These studies
illustrate three CBPR themes: community assessment, setting global priorities, and collaboration in research design.
We propose that further research using participatory principles would be useful in accelerating the pace of discovery
and the development of clinically meaningful biomarkers. For this goal to be successful we advocate for increased
attention to previously identified conceptual and methodological challenges to participatory approaches in health
research, including improving scientific rigor and developing long-term partnerships among stakeholders.
Keywords: Autism, Community-based participatory research, Biological markers
Background
A biomarker is a stable and objective indicator of biological
state. The search for biomarkers associated with autism
spectrum disorder (ASD) is currently underway [1–3].
Among the potential uses of biomarkers are the following:
biomarkers for susceptibility indicate a predisposition for a
condition such as the presence of a genetic variant associ-
ated with autism [4]. Presymptomatic biomarkers can iden-
tify an individual developing the condition before overt
behavioural symptoms are noticeable. For example, brain
imaging techniques such as electroencaphalography are
being researched to help distinguish infants at higher risk
for autism before behavioural symptoms manifest [5].
Biomarkers can also be used as a diagnostic tool: in autism,
chromosomal microarray analysis has been recommended
as a first-tier diagnostic test for autism to supplement
behavioural diagnostic procedures, clarifying the presence
of diagnosable genetic conditions [6, 7]. Finally, biomarkers
may also be prognostic i.e. to predict the outcome of a
condition to allow for tailored and targeted treatments. All
of these biomarkers have the potential to accelerate detec-
tion of ASD and access to tailored services for improved
outcomes for those with ASD and their families.
There are challenges in translating research on bio-
markers in the clinic [8]. Firstly, what precisely should
these biomarkers map onto in ASD and at which develop-
mental time-point? Considering the condition’s hetero-
geneity [9–12] and its developmental nature [13] deciding
on the impairment at a certain time-point to which a
biomarker can predict is challenging. Secondly, a per-
son’s position on the spectrum is not fixed throughout
life [14–16], making biomarker measurement sensitive
to a person’s development. Finally, discovered bio-
markers thus far have poor sensitivity and specificity
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when applied to the general population, limiting their
utility in community-based care [8].
Such challenges in translating biomarker discovery to
clinical applications have been often deliberated in bioeth-
ics. This includes discussion of ethical issues related to
bio-banking, prenatal or population screening, and direct-
to-consumer testing [17–19]. We have previously argued
that issues related to translating biomarker discovery are
much broader at the intersection of scientific, social, and
health systems challenges [8]. Effective knowledge transla-
tion in this area relies on engagement of key stakeholder
groups, the intended beneficiaries of this research.
Engaging stakeholders in this area would inform re-
searchers of questions relevant to stakeholders. Thus, end
products of this research would address stakeholders’
needs and circumvent potential harms, accelerating ap-
propriate translation of biomarker discoveries. However,
the extent to which stakeholders are engaged in biomarker
discovery is currently unclear and some have suggested
that biomarker discovery is on the whole discordant with
stakeholders’ needs [20, 21]. Our goal is to systematically
evaluate these claims.
To achieve this goal, we adopt a framework of
community-based participatory research (CBPR) as it re-
lates to autism biomarker discovery. CBPR aims to support
active engagement of the community in research through
equitable and sustainable partnerships between researchers
and a unit of community [22]. Given that theoretical de-
bates presented have been extensive, we focus on two areas
that have not been sufficiently elaborated on before. First,
we evaluate the potential challenges in CBPR application to
biomarker discovery. Secondly, we systematically assess the
quantity and quality of empirical biomarker discovery stud-
ies that adopt CBPR principles. We begin with a brief over-
view of CBPR.
Principles of community-based participatory research
CBPR encompasses a range of approaches that support
community involvement in research. These approaches
can operate in a wide range of research designs and in-
volve diverse groups and populations [23]. In CBPR,
both community and researcher enter into an equitable
partnership to address research questions deemed rele-
vant to the target community [22, 24].
Historically, the roots of CBPR can be traced back to two
periods: 1) research aimed to bridge the theory-practice gap
and 2) efforts to empower marginalized groups when the
academic institution was critiqued as being too distanced
from social problems [25]. The WK Kellogg Community
Health Scholars Program was the first to conceptualize a
common definition of CBPR, leading to CBPR “founda-
tional books” [24–26]. Within this program, Israel et al.
[27] outlined nine specific core principles of CBPR: recog-
nizing a “community” as a unit of identity, leveraging on
strengths and resources of both the community and
researchers, facilitating collaborative, equitable, and long-
term involvement of all partners in a cyclical and iterative
manner in all phases of research [27]. CBPR also promotes
co-learning and empowering that attends to social inequal-
ities and addressing health from both positive and ecologic
perspectives while balancing investments into knowledge
and intervention for mutual benefit of all partners. These
principles are considered ideal goals to strive toward, con-
cretely built on the following core components of CBPR
[28]:
1. Forming a CBPR partnership
2. Assessing community strengths and dynamics
3. Identifying priority local health concerns and
research questions
4. Designing and conducting etiologic, intervention,
and/or policy research
5. Feeding back and interpreting the findings
6. Disseminating and translating research findings
7. Maintaining, sustaining, and evaluating the
partnership
The applications of CBPR are far-reaching and flexibly
adapted based on the type of research [23]. The nature of
“partnerships” of the community can vary from commu-
nity representatives acting as an advisory board to
researchers [24], to the community directing research pro-
jects with researchers only providing technical expertise
[29]. CBPR also differs on the intended outcome of the
partnership: some partnerships grew to overcome a com-
munity’s distrust of research groups from previous nega-
tive experiences [30], while others were developed to
enhance the uptake of findings in the community [23, 31].
Conceptual challenges to CBPR as they apply to
biomarker discovery in autism
Despite apparent advantages, CBPR poses significant and
previously recognized conceptual challenges in health
research. These challenges include ensuring proper repre-
sentation of a community [32], forecasting long-term
impacts of basic research [33, 34], and threats to internal
validity, specifically concerns for decreased randomization
and contamination [35]. We consider how each challenge
relates to biomarker discovery and its respective solution.
Stakeholder definition
Among the most frequently recognized challenges to
CBPR is how to adequately represent the “community”
[35–37]. In participatory research, there is a potential dan-
ger of selection bias, where highly outspoken subgroups
may not represent the broader population [35]. We have
previously discussed the complexity of defining ‘stake-
holders’ in autism research, noting that ‘stakeholders’ have
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diverse needs, may benefit from research advances differ-
ently, and have varying interest in involvement in research
[38].
In the case of biomarker discovery, strong claims of an
inherent conflict between researchers and ‘stakeholders’
are presented often without defining who the ‘stake-
holders’ are [20, 39]. Homogenizing the stakeholder
group is unhelpful because needs faced by individuals
with autism and their families are as heterogeneous as
the condition itself [8] and moderated by contextual,
geographic, and socio-cultural factors [40, 41].
Views differ on what autism even is: some advocate
groups endorsed a search for a “cure” for autism, a view
neurodiversity proponents find objectionable because aut-
ism is considered part of “natural human variation” [8, 42].
When perceived by some stakeholders as a means to find a
“cure”, biomarker discovery becomes much more contro-
versial [8]. On the other hand, biomarker discovery is
considered a research priority to a geographically and
culturally diverse group of stakeholders if such biomarkers
were to facilitate identification and timely access to care
[40, 41]. Moreover, it seems likely that biomarker discovery
is a more relevant priority depending on the developmental
pathway of the person affected: parents of children sus-
pected of or recently diagnosed with autism may be more
likely to find value in prospective, diagnostic, or prognostic
biomarkers relative to families whose children have been
diagnosed for several years.
Therefore, stakeholder representation is a major chal-
lenge in public engagement in autism research in general
[38], applicable to biomarker discovery. The term stake-
holder is context-dependent, does not always mean benefi-
ciary from research and not all stakeholders will want to
be or can be adequately represented and engaged [38]. For
successful stakeholder engagement to be achieved, a sys-
tematic assessment of priorities, needs, and experiences of
the stakeholder group is needed.
Forecasting consequences
The second major challenge for CBPR relevant for bio-
marker discovery lies in foreseeing potential social con-
sequences of any discovery. This is due to the difficulty
in predicting the potential ripple effects of understand-
ing the mechanism of a gene, and the fact that know-
ledge advances in incremental steps by building upon
previous discoveries. This general challenge in health
research [43] has been previously recognized in autism
biomarker discover. On the one hand, premature in-
volvement of the community in a new discovery before
it has proven clinical value would inflate public expecta-
tions, leading to a subsequent loss of public trust in
science when these hyped promises are not met [8]. On
the other hand, the lack of community engagement has
been shown to lead to a loss of public trust in science.
An example comes from the national partnership with
Aboriginal representatives, where community represen-
tatives expressed that “Aboriginal communities have
been researched to death” and unequivocally objected to
any further research [44]. After extensive deliberation,
representatives agreed that a health survey would be
acceptable, but only with an equitable partnership be-
tween Aboriginal representatives and researchers in the
project. Similarly, Arbour and Cook presented examples
of respectful genetic research under the concept of
“DNA on loan” in understanding the mechanism of a
rare chromosomal abnormality in a First Nations com-
munity [30]. The group first discussed the research pri-
orities with the family to develop trust with them.
Participating families were then kept updated with the
research progress. Later the group facilitated informed
health care and counseling for each family based on
their findings. The community and family themselves
determined whether or not the specification of First
Nations could be used to promote health in the wider
community, thus allowing the community to weigh the
possibility of stigma with the potential benefit of re-
search for others.
These examples illustrate that the challenge of fore-
casting research results can be mitigated through active
consideration of research priorities and process with par-
ticipating families. Such involvement also led to benefits
for both groups: the community protected themselves
from possible stigma and received informed care and
counseling, while the research group was able to address
their research question and advance knowledge in their
field.
Internal validity
A third major challenge of participatory research is the
threat to internal validity. A systematic review of CBPR
showed that despite the wealth of studies adopting this
approach, limited studies have reported a complete
intervention with authors only detailing either their
findings or study methodology [35]. This made it diffi-
cult to conclude if participatory research is associated
with low scientific quality [35]. Nevertheless, concerns
of decreased randomization and contamination in CBPR
remain [35, 45].
This problem is faced especially in randomized con-
trolled trials (RCTs), a methodology with clearly defined
standards of scientific rigor. In RCTs, participants ran-
domly allocated to the control group must not be exposed
to the intervention and vice versa, causing contamination.
Because members of the community work closely with
each other and with researchers on the research project in
CBPR, the likelihood for decreased randomization and
contamination among individuals is high [45].
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However, the disappointing results of some non-
participatory “high-rigor” RCTs have shown that the
improved adherence to interventions found in CBPR
along with the unintended benefits of partnerships may
outweigh the concern for these threats, all of which can
also be mitigated. Authors of a well-designed nationwide
RCT (see COMMIT trial [46]) admitted that the lack of
community involvement in their trial was the biggest
contributing factor in its disappointing outcome, and
that “an exclusive focus on risk factors alone may be in-
appropriate” [47]. In contrast, Andrews et al. worked
closely with the community in a tobacco cessation inter-
vention and implemented randomization at the commu-
nity level to reduce the risk of reduced randomization
and contamination [48]. Because of the partnership, they
not only showed promising outcomes on smoking cessa-
tion, they also reported high retention rates (87 %) and
improved self-efficacy for both the community health
workers implementing the intervention and the partici-
pants receiving the intervention [49]. Therefore, as pro-
posed for other areas of health research [35], CBPR has
the potential to enhance the quality of conventional
research methods for biomarker discovery in autism by
increasing participation rate, lowering drop-off over time
where applicable, and increasing capacity for the com-
munity and individual to adopt the findings, such as a
new test or an intervention.
Taken together, the above considerations suggest that
participatory research is neither conceptually nor meth-
odologically in conflict with biomarker discovery in aut-
ism. Nevertheless, the extent to which there is underlying
conflict between biomarker discovery specifically and par-
ticipatory research is a question that continues to be de-
bated [21].
Despite the wealth of theoretical positions and argu-
ments, what remains largely unknown is whether princi-
ples of CBPR have already been adopted in biomarker
discovery. Understanding how to achieve participation in
this field can resolve these theoretical debates and contrib-
ute to future development of biomarker discovery [38].
Methods
We use scoping review methodology to address the
question of how to achieve participation in biomarker
discovery. A scoping review methodology [50, 51] allows
the mapping of key concepts of participation to a com-
plex research area. Unlike systematic reviews that focus
on a narrow question with specific study designs decided
a priori, our use of scoping review methodology would
include a broader range of study designs and help us
understand the state of the evidence in a field. There-
fore, the selected methodology is appropriate consider-
ing the lack of knowledge on what exists in participatory
approaches in autism biomarker research.
The goal of the study is to identify previous applica-
tions of CBPR in autism biomarker discovery. Because
the state of the science of CBPR in biomarker discovery
is unknown and may be limited, we adopt a broad but
systematic definition of CBPR as articulated by Israel
et al. [27]. While not all principles are suitable to all
forms of stakeholder engagement, there is general agree-
ment that these principles are likely to characterize ideal
partnerships.
Studies were included if they met each of the following
criteria:
1. The study should involve one or more of the following
key stakeholder groups: a person with ASD, families of
individuals with ASD, professionals in the field of ASD,
or policy makers. While we had these categories of
stakeholders a priori, we did not specifically limit the
search strategy targeting specific groups to have a
higher chance of retrieving relevant articles;
2. To increase the chances of retrieving possible
studies, “involvement” of stakeholder groups in
research was defined broadly. This would also
capture any study that performed community
assessment and diagnosis. Thus, any study that
obtained individuals’ views regarding biomarker
discovery that could potentially be used to shape
future research would be included;
3. The topic of discussion in the study included
biomarkers for identification and intervention in
autism, including but not limited to genetic testing
and brain imaging;
4. The study was conducted in English;
5. Original empirical research (quantitative or
qualitative) were included.
Exclusion criteria were:
1. Reviews and opinion papers;
2. The study involved childhood conditions other than
ASD;
3. The study only assessed associations between
potential biomarkers and ASD symptoms;
4. The study reported on collaboration between any of
the above key stakeholder groups and researchers on
topics other than biomarkers for ASD e.g. in
implementing interventions.
We searched Medline, CINAHL, PsycINFO, and
Embase using a comprehensive list of search terms.
Author lists and references were also cross-referenced
for potentially relevant articles. Once key articles were
identified, we retrieved a list of articles that cited those
key articles as well. The search was completed on June
17th, 2014.
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Articles were screened first by title and abstract based
on the above inclusion and exclusion criteria. Screened
articles were retrieved for full text articles. Using a data
extraction form, we extracted relevant study characteris-
tics (e.g. document classification, study design, method
employed, study population, main outcomes). For quanti-
tative studies, we employed a narrative method, wherein
results of studies were compiled and organized to form a
“composite” understanding of the current state of know-
ledge [52]. For qualitative studies, the data extraction form
contained codes that were recursively applied [53]. In
other words, we first developed an initial coding scheme
based on the nine CBPR principles articulated by Israel
et al. [27]. The initial coding scheme consisted of broad
categories namely definition of community, outcomes for
collaboration, the stage of research at which collaboration
occurred, and the evaluation of collaboration. We revised
the coding scheme appropriately after applying it to an
article; for example, articles that elaborated on the defin-
ition of community required additional codes such as
community attitudes, awareness and needs. These add-
itional codes were then retroactively applied to all articles
[53]. This work conformed to the Declaration of Helsinki
and was approved by McGill University Institutional
Review Board.
Results
Our search yielded a total of 342 studies (Fig. 1). After
screening the articles first by title and abstract, 73
articles were retrieved for full-text assessment. Out of
these 73, only seven examples of original research stud-
ies fit with our inclusion criteria. While all possible types
of biomarker testing were targeted in the search strategy,
all studies captured except for one focused on genetic
testing. Similarly, while all possible stakeholders were
considered, studies have only involved parents of chil-
dren with autism.
A synthesis of these seven studies yielded three themes
that correspond closely to previously articulated principles
and components of CBPR [22, 27]. The first is “assessing
community strengths and dynamics” by identifying stake-
holder attitudes and expectations towards the application
of autism biomarkers in their lives. The second is “identi-
fying priority local health concerns and research ques-
tions” by collaborating with stakeholders in setting long-
term priorities for autism research. The third is in “design-
ing and conducting etiologic research” by collaboration
among stakeholders in devising an imaging protocol. In
what follows, we synthesize and critically review identified
evidence for each of these themes.
Identification of stakeholder perceptions and attitudes
While community assessment by itself is not CBPR, it is
an essential component in establishing partnerships with
the community prior to initiating CBPR, and in line with
one principle of CBPR in defining the community of inter-
est by “assessing community strengths and dynamics”
[27]. Considering the dearth of CBPR in the field of
biomarker discovery in general, and in the field of autism
biomarkers in particular, we considered what empirical
work has previously focused on community assessments.
We identified four studies that examined community
attitudes towards one biomarker measurement for ASD:
genetic testing. They mainly surveyed and/or inter-
viewed parents of children with autism on their attitudes
towards genetic testing, and their experience in and
motivation for undergoing testing. On the whole, many
parents are ‘supportive’ of genetic testing for ASD. Using
semi-structured interviews (n = 42), Chen et al. found
that 69 % of parents favoured genetic testing for ASD
[54]. Another study using an Internet survey (n = 25)
Fig. 1 Flow diagram of the progression of inclusion of articles
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showed that 80 % of parents with a child with ASD
would want their younger undiagnosed child tested for
an increased risk for ASD even if the test could not
confirm or rule out a diagnosis [55]. Those who sup-
ported genetic testing do so because they believe it
would support early intervention and treatment, help
families understand the etiology of autism, and inform
family planning [54]. Parents specifically noted that gen-
etic testing could alleviate guilt and promote acceptance
of the condition [56].
While many were in favour of genetic testing, those
against did not foresee its value because they perceived
ASD as “incurable”, they perceived no impact for genetic
testing in the child’s lives or for future pregnancies, and
they have no family history of ASD [57]. Another study
found the fear of stigma from testing was also another
reason for opposing it [55].
Taken together, these studies have obtained perspectives
on genetic testing for autism through qualitative and quan-
titative methodologies. Several limitations of the studies
hinder the generalizability of their findings. Despite multi-
plicity of stakeholders in autism, only parents were the
focus. Two of the studies relied on genetics research data-
bases for recruitment, thus there is the possibility of a
biased sample. The studies represented views of stake-
holders on genetic testing within potentially very different
contexts: research versus clinical practice. Moreover, the
use of Internet surveys is useful in capturing a large num-
ber of respondents, but the survey instrument may only
reflect items of interest to the researchers. While two of the
studies employed semi-structured interviews, their report-
ing of results lacks methodological coherence, reflexivity of
researcher’s role, and method of triangulation [58, 59].
In sum, while some studies have attempted to empirically
examine stakeholder perspectives, these studies are charac-
terized by methodological limitations, which impacted the
generalizability of the findings. To draw valid conclusions
about the perspectives of stakeholder groups on biomarker
discovery, improved attention to recruitment methods and
clarity of constructs assessed are vital.
Collaborative priority-setting
No research projects in autism biomarker discovery have
yet to involve participants in determining research ques-
tions directly. However, in line with the CBPR principle
of recognizing priorities identified by the community
[27], two studies focused on obtaining long-term prior-
ities for autism research from the community [21, 60].
In addition to student group discussions, Higashijima et
al. invited a diverse array of community members to
monthly public science cafes through a variety of re-
cruitment methods that included parents of children
attending nurseries catering to ASD, and employees of
childcare services. These community members discussed
their views on the relationship between autism research
and society with the guiding question, “Towards the
construction of an autism-friendly society, what is the
most impressive/important thing for you after finishing
the conversation in today’s café discussion?” Discussion
points were then analyzed to produce a list of topics that
the community would want to discuss further. This list
was then used to develop a survey, which was sent out to
the larger community to further refine the discussion pri-
orities. Survey results were then presented to researchers
in a 3-day event dedicated to foster a discussion on creat-
ing an “autism-friendly society.” Points included in the
final social agenda for autism research that needs further
discussion included the following: ASD research for a
cure, definition of ASD, issues surrounding ASD diagnosis
and content for dissemination to the public.
Pellicano et al. employed focus groups and survey meth-
odology to obtain views of 1,517 members of the autism
community on the current landscape of autism research in
the UK, along with their research priorities for the future
for all fields of autism research [21]. Many participants
called for a more balanced distribution of funding across
the different research areas. When asked about their prior-
ities for future autism research, participants endorsed re-
search on support and services, efforts to improve public
knowledge about autism, and of greater investment into
autism research in general. The online survey showed that
participants unanimously agreed that all research questions
are important, with subtle differences (from “moderately
important” to “very important”) between groups on specific
questions. The research questions most frequently en-
dorsed as important by autistic adults, practitioners, and
family members are understanding how to improve life
skills of autistic adults, how to meet their needs through
public services, how autistic people think and learn, and on
the future prospects for autistic adults.
The two studies outline the feasibility of setting prior-
ities in a safe and open environment for both scientists
and community members. Despite the relatively large
samples, both studies present limitations. They employed
convenience sampling to maximize participation, without
formal consideration of representativeness to a target
population, or even a specific definition of what target
population was intended. Moreover, groupings of partici-
pants with the expectation that most within one group
will share the same views is a potentially reductionist
approach not reflective of real-world complexity. For ex-
ample, a “researcher” group is not a meaningful category
when properties of the researcher are unknown e.g. the
researcher’s field of research, career stage, and focus
populations.
Other potential risks to generalizability introduced by
the two studies are ambiguous content and biased framing
of the question. For example, one study asked participants
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if they were satisfied with the pattern of funding for
research. Yet, the categories for research funding were
presented as “biology” vs. “intervention”, potentially mis-
leading community participants that research in one area
is more likely than the other to directly lead to community
benefits. Participants were asked to discuss their research
priorities after being presented with the pattern of UK
funding. It is possible that participants’ perspectives chan-
ged after deliberating over an investment “unbalance” in
research funding.
Overall, the ongoing considerations highlight the com-
plexity of surveying and/or deliberating research priorities.
Notably absent is the use of well-established deliberation
approaches abundantly used in global health research,
such as the Delphi technique [61] and stakeholder dia-
logue [62].
Collaboration in research design
One study we identified illustrates feasibility and value
of collaboration with the community in design [63], in a
way that strengthens conventional research methods and
“building on strengths and resources within the commu-
nity” [27]. Nordahl et al. collaborated with parents in
designing a magnetic resonance imaging (MRI) protocol
without the use of sedation for their child. Typically,
imaging research in ASD requires children to be anes-
thetized to limit movement during imaging. As a result,
imaging research without the use of sedation in ASD is
limited to high-functioning children [64], who may not
represent others on the spectrum. Nordahl et al. suc-
ceeded in obtaining quality scans of 93 % of their partici-
pants without sedation by collaborating with parents of
children who participated. The research team first pre-
pared a handout to describe the MRI protocol to the
parents and child. With the parents, they then developed
an individualized strategy guided by a questionnaire that
assessed the child’s sleep patterns. They followed this
individualized strategy during the experiment by recreat-
ing the child’s bedtime routine and sleeping environment
at the imaging center. Parents reported positive feedback
on the experience. This study demonstrates that it is
feasible to include parents in the design of a study
protocol and to ascertain feedback on their experience.
Notably, such collaboration allows researchers to better
address their research questions while catering to the
immediate needs of families.
Discussion
Our review has revealed limited albeit clear empirical ex-
amples of participatory research in autism biomarker dis-
covery. Applications of CBPR have addressed three areas:
1) understanding of needs and priorities of a target com-
munity, 2) long-term priority setting with the community,
and 3) collaboration in research design. Despite the fit of
these empirical studies with CBPR principles, it appears
surprising that their number is so limited given that bio-
marker discovery is an area of major investment and the
emerging literature advocating the need for community
engagement. What our review could not address is
whether similar approaches have already been used in bio-
marker discovery but their findings not published.
What possible barriers might explain the lack of CBPR
applications in biomarker discovery? One possible barrier is
the sheer complexity of engagement in this area. The con-
dition impacts a multitude of diverse communities, each
with a complex group of stakeholders whose attitudes and
perspectives are variable. What is clear based on our find-
ings is that previously identified potential challenges of
participatory research are more likely whenever the stake-
holder group is not defined as a coherent and meaningful
sample. Considering that conducting a community assess-
ment and diagnosis prior to partnering with the community
is a “key factor” in the success of carrying out community-
based participatory research generally [22, 31, 65], defining
the community of interest would then be an essential first
step in adopting CBPR in autism biomarker discovery.
More generally, autism research is ‘reinventing the wheel’
in adopting participatory elements, instead of building on
experiences and models in similar areas of health research.
For example, a group of researchers working with small Al-
askan native communities have proposed a CBPR-approach
to conducting genetic studies for complex conditions (obes-
ity, diabetes, and cardiovascular disease) and sharing these
results to maximize the potential benefit and understanding
[66]. The research team held open dialogue sessions be-
tween the researchers, the tribal council, and community
representatives from their Yup’ik Eskimo study population,
in which genetic education workshops were paired with
discussions on Alaskan Native culture to create culturally
respectful experimental protocols. Community involvement
occurred throughout recruitment to prevent group harm
and stigmatization. When results were ready, consultations
with the community helped produce culturally relevant
formats for presentations. Dissemination of the results was
made in Yup’ik with the presence of at least one research
member to answer questions. Such a format serves as an
important framework from which biomarker discovery in
autism could be feasibly adapted.
A further challenge is that the notion of ‘conflict’ between
researchers and the community assumes a false distinction
between two groups and suggests that one is expected to
yield to the views of the other. Yet, advancement of
knowledge does not occur in a vacuum – society is rarely
impervious to its long-term benefits and detriments. Con-
tributions by autistic researchers and advocates to debates
on research priorities within mainstream scientific journals
[67, 68] have also blurred the boundaries between “commu-
nity” and “researcher”. Autism research is vulnerable to
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funder and public pressure that may undermine the
value of scientific discovery and advancement of know-
ledge [8, 38]. Such pressures may be, in part, why scien-
tific priorities were historically driven by what turned
out to be simplistic promises, such as a “gene” for aut-
ism [8, 38].
Our findings suggest that available data are currently
too limited to evaluate the claim that biomarker discov-
ery is indeed misaligned with other stakeholder perspec-
tives [20, 21]. Available studies were not only few, but
also were characterized by methodological limitations
impacting generalizability. When pushed towards po-
lemics, conflicting priorities between researchers versus
the public become a false notion lacking pragmatic real-
world value.
Conclusion
We suggest that deliberation around the intended out-
comes of research, both short- and long-term, would
instigate the same progress seen in other areas of health
research, while mitigating concerns around participation.
We propose that re-conceptualizing biomarker discovery
in autism as participatory would entail clarifying and
increasing its social relevance, enhancing rather than
undermining its rigor, and accelerating its intended ben-
efits to society. The success of this vision will rest on
long-term partnerships among stakeholders to achieve
enhanced public trust and engagement in science that
would yield benefits to all involved.
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